Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical needs: orphan tauopathies, Alzheimer’s and Parkinson’s disease.

Products, services, technology

Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including one first in class for Parkinson’s disease, one best in class in Alzheimer’s disease and related disorders.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business